Tailor-made and customized data intelligence databases, trends and insights that solve information challenges and caters organizations needs.
Enables the search and exploration of data to plug in a variety of visualization tools to view information.
Allows data from local and central data sources to be integrated and validated seamlessly with a metadata-driven approach.
Uses statistically defined algorithms, and is up-to-date with the changing compliance and regulatory requirements of the industry.
Sciinov Insights offers a centralized data repository that caters data intelligence databases, trends and insights to satisfy your individual and organizational objectives. We keep you informed, profound and favorable decisions to encompass the advantages of upcoming trends, progressions, estimations, and opportunities through our precise understanding of the market.
The validated actionable insights provide overall updates from global pharmaceutical companies related to approvals, deals and launch on Daily/Weekly/Monthly basis. Financial Data sorted by Deal Value and global sales of drugs of interest Summary of upcoming events related to drugs of interestRequest Demo
Up-to-date industry updates from Company, Regulatory, SEC, Trial registries and Government websitesView More
Scientific and regulatory approaches gathered, organized and analyzed with unique display and customized exportsView More
Global drug research companies, institutes, universities and goverment bodies coverage with their key metrics and GICSView More
Clinical Trial Intelligence
Trial initiation, recruitment, outcome measures, sites, study co-ordindators, principal investigators and results analysis integrated with drugs and companiesView More
Pipeline and approved drugs discovery and delivery technologies analysis based on new techniques and devices along with companies and deals detailsView More
Drug development leads with its associated contacts by department, titles email and phone and c-suite employees coverage from company websites, SEC filings, trial registries and other public sourcesView More
Drug Pricing Intelligence
ATC code classification, active indredient, route of admin, strength, trade names, MA holder information, approval dates with drug retails price and wholesale price coverage from United States, EU and Japan countries.View More
Anlayzed by companies, drugs, regulatory designations, drug sales and forecast, patent expiries, clinical trials, trial sites, investigators, contacts, technologies, deals, drug prices, generics/biosimialrs and manufacturing information.
Tailor-made customized analysis as per your business needs on companies and regulatory developments helps you to assess the active market players in the industry.
Stay vigilant with market intelligence that keeps you poised for change and a step ahead of competitors.
The team of Research Insights follow stringent security measures to prevent private information from reaching third parties.
Our solution keeps clients up-to-date with the changing compliance and regulatory requirements of the industry.
At The Research Insights, We will help you transform your organization's performance
Report includes repurposed drugs for off label use,
therapeutic drugs such as a small molecule, monoclonal
antibody, protein, recombinant peptide, peptide, recombinant
protein, stem cell therapy, oligonucleotide, synthetic
peptide, fusion protein, gene therapy and immunotherapy.
Report covers 56 drugs and 550+ DMF filings from US FDA, EMEA
and Japan. 2019 sales are more than USD 50bn for the 56 to be
expired drugs. 220+ DMF filers across US FDA, EMEA and Japan
Report covers 5,900 drugs and 1,400 companies with ER, MR,
DR, SR, PR and XR formulations. Report covers 36 countries
Innovator and Generic drug approvals. Comprehensive report
helps to build strategy for the new formulations.
Emerging report as regulatory bodies insisting drug approval
along with diagnostic. Report covers 220+ CDx along with 150+
drugs and 50+ companies. Pandemic diseases burst especially
COVID-19 signifies the importance of efficient, low cost and
Report covers 550 approved drugs and 139 Innovator drug
companies. Drug patents analysis by country & projected
generic launch, sales and Forecast data: 2012 - 2036.
Posology information includes route of admin, dosage and
US Branded companies reducing patent litigation costs through
agreements with generic companies. Prasco, Greenstone, ANI
and Oceanside are specialized Authorized Generics (AZ)
companies. Reports exclusively covers 112+ drugs and 55+
Drug regulatory designations are the important milestones for
US FDA, EMEA and PMDA approvals. For the duration 2014 -
2019, Roche & Takeda companies hold 32 orphan designations,
Novartis (30), BMS (29), Amgen & Gilead (20 each) are the top
regulatory designated companies.
2019 showcase the increased growth in the drug acquisitions
to strengthen the pipeline portfolios. BMS' Celgene
acquisition worth USD 89.5bn is third highest ever pharma M&A
in 2019, Pfizer acquired Array, Novartis acquired The
Medicines, Eli Lilly acquired Loxo Oncology and Roche's Spark
Therapeutics acquisition are the five top M&A's in 2019.
2019 US FDA NME approvals includes 55% from regulatory
designations. Out of 41 approvals, 9 for cancer, 7 nervous
system indications, 6 infectious diseases, 4 haematology and
3 immunology indications are top 5 disease areas. Reports
exclusively covers 300+ drugs and 172+ companies.